Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy.
about
Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma.Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer.Suppression of Akt-HIF-1α signaling axis by diacetyl atractylodiol inhibits hypoxia-induced angiogenesisPredictive molecular biomarkers to guide clinical decision making in kidney cancer: current progress and future challenges.A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.Ursolic acid-loaded chitosan nanoparticles induce potent anti-angiogenesis in tumor.Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review.Tyrosine kinase inhibitor sunitinib therapy is effective in the treatment of bone metastasis from cancer of unknown primary: Identification of clinical and immunohistochemical biomarkers predicting survival.Extracellular vesicles isolated from human renal cell carcinoma tissues disrupt vascular endothelial cell morphology via azurocidin.Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients.Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.Aberration hubs in protein interaction networks highlight actionable targets in cancer.
P2860
Q35995721-C6E61E3D-BB9D-4978-8547-97B10A5A0043Q37151272-9349A0FB-DFFC-413E-8B35-F76829B0BB99Q37581083-2182A2D4-434B-47D9-8C9F-432E31E40FA8Q38402997-396BE0EA-267A-436F-8920-0FBE5477A6DDQ38720430-D4994543-C780-4DFD-A59A-FA87C4D19592Q38793751-CF1A48BD-B8F8-449F-B9A5-4D0CC045AE65Q39095254-8627EE10-8836-40F7-AD8D-E5DD00364BCCQ40761584-AB2EE128-652B-4FBE-84AF-A042C6CB7F75Q47702301-201D09AF-DB0E-487E-9873-D2154679AEE5Q51652607-2BABE135-4003-482C-92B4-902966FB091EQ52582783-41DE699A-9278-4A8F-9736-E9C6CE217AC7Q54977244-0411BB1A-CCC4-4782-BB7F-7BB7BF62C258
P2860
Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Active angiogenesis in metasta ...... it to sunitinib-based therapy.
@en
type
label
Active angiogenesis in metasta ...... it to sunitinib-based therapy.
@en
prefLabel
Active angiogenesis in metasta ...... it to sunitinib-based therapy.
@en
P2093
P2860
P356
P1476
Active angiogenesis in metasta ...... fit to sunitinib-based therapy
@en
P2093
A Borrero-Palacios
I Cristóbal
J García-Foncillas
J Madoz-Gúrpide
J Martínez-Useros
L del Puerto-Nevado
M Rodríguez-Remírez
P2860
P2888
P304
P356
10.1038/BJC.2014.225
P407
P577
2014-05-01T00:00:00Z
P5875
P6179
1001051024